731results about "Peptide libraries" patented technology

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

VH domain, in which: (i) the amino acid residue at position 1 12 is one of K or Q; and / or (ii) the amino acid residue at position 89 is T; and / or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 1 10 is one of K or Q; and (iv) in each of cases (i) to (hi), the amino acid at position 1 1 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).

Provided herein are methods for capturing an analyte from a first region of interest of a biological sample on a substrate, where the biological sample comprises the first region of interest and a second region, and where the method includes contacting the second region with a sealant in order to create a hydrophobic seal thereby preventing an interaction between an analyte from the second region with a capture domain of a capture probe.

The invention discloses preparation of a human CD56 immune phage display antibody library, which comprises the following steps: S1, animal immunization: expressing recombinant hCD56 protein in escherichia coli, then immunizing a Balb / c mouse, and detecting immune titer; s2, splenocyte preparation: extracting RNA (Ribonucleic Acid) of immune mouse spleen cells, and performing reverse transcription to obtain cDNA (Complementary Deoxyribonucleic Acid); s3, preparation of an initial bacteriophage display library: amplifying a heavy chain variable region and a light chain variable region by using a PCR technology, and then assembling to form scFv; constructing scFv phagocytids, electrically transforming the scFv phagocytids into TG1 competent cells, and constructing a bacterial library; s4, constructing a phage single-chain library of the hCD56: infecting the bacterial library by using a helper phage M13K07, and constructing a phage single-chain antibody library; and S5, elutriation and screening of a phage library: specifically enriching a phage single-chain antibody library, screening positive clones from the phage single-chain antibody library, and determining a sequence. According to the invention, the human hCD56 antibody scFv sequence fragment can be screened out, and the research and development period is shortened.

The invention discloses a recombinant fusion protein of a human lambda light-chain single-chain antibody, a DNA (deoxyribonucleic acid) molecule, a library building method and application, and the recombinant fusion protein of the human lambda light-chain single-chain antibody is the recombinant fusion protein formed by connecting the human lambda light-chain single-chain antibody, phage Piii protein and luciferase, the amino acid sequence of the recombinant fusion protein of the human lambda light-chain single-chain antibody is shown as SEQ ID NO: 5, the recombinant fusion protein library of the human lambda light-chain single-chain antibody has large capacity, the established single-chain antibody TG1 library is more than 1 * 10 < 9 > cfu / mL, positive clones capable of being combined with ligands can be screened and enriched for multiple rounds, and the recombinant fusion protein library has the characteristics of high sensitivity, high signal-to-noise ratio and the like.

To provide a biochip and a manufacturing method in which the problem of overflow of a liquid specimen is avoided, and which can deal with a large amount of the liquid specimen.SOLUTION: A biochip comprises a substrate 110, an insulator layer IL, a semiconductor layer 120, a dielectric layer 130, a metal layer 140, and a protective layer 150. The semiconductor layer is disposed on the insulator layer, and has a reaction zone 121. The dielectric layer is disposed on the semiconductor layer, and has a first aperture O1. The metal layer is disposed on the dielectric layer, and has a source, a drain and a wall structure. The wall structure 141 surrounds the first aperture, the source and the drain. The protective layer is disposed on the metal layer, and has a flat part 151, a protruding part 152, a second aperture O2, and a third aperture O3. The flat part surrounds and defines the second aperture. The protruding part is disposed to correspond with the wall structure. The protruding part surrounds and defines the third aperture. The second aperture connects the third aperture and the first aperture, and allows the reaction zone to be exposed.SELECTED DRAWING: Figure 6

Provided herein are peptide compositions derived from regenerative species regenerative proteins, and methods of making and use thereof, that seek to reduce fibrosis. The disclosed peptide formulations and compositions may be used to reduce fibrosis resulting from any disease or disorder, e.g., fibrosis associated with tissue inflammation, wounds, disease, or infection.

The invention belongs to the technical field of biology, and particularly relates to a differential characteristic polypeptide library for identifying different medicinal parts of bufo bufo gargarizans and application of the differential characteristic polypeptide library. In the prior art, toad venom is different from toad skin, toad meat and toad bone in protein components, but detection of protein macromolecules is tedious, and conversion from a method to a standard is not facilitated. The polypeptide is used as an index component to identify and analyze the venenum bufonis and dried toad medicinal materials, the specificity is high, the stability is good, the interference of the processing process is avoided, multiple medicinal materials can be identified at the same time, and the advantages are obvious.

The invention relates to a method for screening a human-mouse cross MR1 restriction high-affinity TCR (T cell receptor) by using a phage display technology, and relates to the technical field of T cell receptors. According to the invention, a phage display technology is utilized to prepare an MAIT cell single-chain T cell receptor (scTCR) phage library, the scTCR phage library is subjected to biological elutriation through an MR1 / 5-OP-RU tetramer, and Phage-ELISA identifies that TCR6 clone (TCR6) has specific binding with human and mouse MR1 / 5-OP-RU and has higher affinity compared with other clone.

Kits and methods of analyzing macromolecules, including peptides, polypeptides, and proteins, using nucleic acid coding are disclosed. Sample analysis kits employ nucleic acid coding and / or nucleic acid recording of molecular interactions and / or reactions, such as recognition events (e.g., between antigens and antibodies, between modified terminal amino acid residues, or between small molecules or peptide therapeutic agents and targets, etc. Additional barcoding reagents, such as reagents for cycle-specific barcoding (e.g., "timing"), compartment barcoding reagents, combined barcoding reagents, spatial barcoding reagents, or any combination thereof, may be included in the kit. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may produce molecular interaction and / or reaction information, and / or polypeptide sequence information. The kits can be used for high throughput, multiplexing and / or automated analysis, and are suitable for the analysis of proteomes or subsets thereof.

Disclosed herein are mRNA display libraries comprising peptides with non-canonical amino acids and methods of making the mRNA display libraries which may include a plurality of mRNA-linker-macrocyclic peptide molecules comprising AcTyr-[amino acid]m-[PhSec]-[amino acid]n-[Cys]-[linker]-[mRNA]; wherein m and n are each an integer from 0 to 30; and wherein each macrocyclic peptide comprises a thioether linkage and is according to formula I: wherein R comprises [linker]-[mRNA].

The invention relates to a method for producing nano-arrays and micro-arrays. The method described herein provides a method of generating an array of spatially separated proteins. The method relies on covalently attaching each of a plurality of proteins to a structured nucleic acid particle (SNAP) and attaching the SNAP to a solid support.

The present invention relates to the identification of antibodies and / or antibody fragments in a selection process. The present invention relates to a method, a system and a computer program product for identifying pairs of genes which encode the variable domains of light and heavy chains of selected antibodies and / or antibody fragments.

Disclosed are fusion proteins (and homodimers and heterodimers thereof). Fusion proteins can bind to a protein of interest and to an internalizing receptor (transferrin receptor) on a cell surface. Once bound, the protein of interest can be internalized and / or degraded inside a cell.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The present inventors have successfully prepared a library consisting essentially of a plurality of antigen-binding molecules differing in sequence from each other, the antigen-binding molecules each comprising an antibody variable region that has binding activity against a first antigen and a second antigen different from the first antigen, but does not bind to the first antigen and the second antigen at the same time. Use of the library of the present invention allows the obtainment of a variable region having enhanced ability to bind to the first antigen and the production of a bispecific antibody against the first antigen and a cancer antigen. Moreover, the present inventors have also successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against three different antigens, but does not bind to these antigens at the same time.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

Methods for preparing a personalized cancer vaccine and a method to train a machine learning HLA-peptide presentation prediction model. Further wherein, a method of making a HLA class II tetramer or multimer comprising an epitope, the method comprising contacting a purified soluble HLA-DM loaded with a peptide epitope with a HLA class II tetramer or multimer, thereby forming a HLA class II tetramer or multimer loaded with the peptide epitope, is disclosed.

An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.

Provided are devices and methods for capturing template sample nucleic acids in a spatially specific manner that is coordinated with the original location of the templates in a tissue sample. By preserving spatial information regarding a given sample, the disclosed technology allows for improved diagnostics as well as improved therapeutic decision making for patient care and therapy.

This invention provides a masked antibody having performance superior to that of conventional masked antibodies. The masked antibody is a target-antigen-binding molecule comprising a moiety [a], a moiety [b], and a moiety [c]: i.e., a moiety [a]: a moiety binding to a target antigen; a moiety [b]: a first peptide recognizing a target antigen-binding site in the moiety [a]; and a moiety [c]: a second peptide consisting of an amino acid sequence comprising amino acids that are converted from an uncharged state to a positively charged state in response to a pH change from neutral to acidic conditions at a pH 7.5 or lower.

Kits and methods of using the kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and / or nucleic acid recording of a molecular interaction and / or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Additional barcoding reagents, such as those for cycle-specific barcoding (e.g., “clocking”), compartment barcoding, combinatorial barcoding, spatial barcoding, or any combination thereof, may be included in the kits. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may generate molecular interaction and / or reaction information, and / or polypeptide sequence information. The kits may be used in high-throughput, multiplexed, and / or automated analysis, and are suitable for analysis of a proteome or subset thereof.

PURPOSE: To provide a biochip and a manufacturing method for the same.SOLUTION: A detection unit of a biochip includes a substrate, a first insulating layer, a semiconductor layer, a second insulating layer, a first metal layer, a second metal layer, and a protection layer. The semiconductor layer includes a reaction region. The second insulating layer is disposed on the semiconductor layer, and includes a first part, a second part, and a first opening part for exposing the reaction region. The first metal layer is disposed on the second part and includes a source, a drain, a gate, and a first wall structure. The second metal layer includes a second wall structure disposed on the first wall structure. The protection layer is disposed on the first metal layer and the second metal layer. The protection layer includes a second opening part, a third opening part, and a fourth opening part, and includes a flat part that defines the second opening part by surrounding it, a first projection part that defines the third opening part by surrounding it, and a second projection part that defines the fourth opening by surrounding it. In a normal direction of the substrate, the first opening part, the second opening part, the third opening part, and the fourth opening part overlap with each other.SELECTED DRAWING: Figure 4

To provide recombinant polyclonal proteins and use methods thereof.SOLUTION: Provided herein is a composition comprising recombinant polyclonal proteins (RPPs) derived from mammalian plasma cells or plasmablasts. Methods for using the RPPs are also provided. The RPPs are recombinant, and their sequences are derived from peripheral blood plasma cells or plasmablasts. The peripheral blood plasma cells or plasmablasts are mobilized by, e.g., a vaccine administered to a donor, and the peripheral blood plasma cells or plasmablasts are specifically separated from other peripheral blood cells. The peripheral blood cells can come from any mammal, for example a mouse, a rat, a human, a monkey, a horse, or a cow.SELECTED DRAWING: None

Disclosed are fusion proteins (homodimers and heterodimers thereof). Fusion proteins that can bind to a protein of interest that is a G Protein-Coupled Receptor (GPCR) and to an internalizing receptor on a cell surface (transferrin receptor). Once bound, the protein of interest can be internalized and / or degraded inside a cell.

A method for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding is disclosed.

Provided are a nucleic acid-polypeptide-nucleic acid ternary complex, and a use thereof in polypeptide nanopore sequencing. The ternary complex has the following structural formula: single-stranded nucleic acid 1-polypeptide-single-stranded nucleic acid 2, the single-stranded nucleic acid 1, the polypeptide and the single-stranded nucleic acid 2 being covalently linked in sequence, the single-stranded nucleic acid 1 being used to connect with a sequencing adapter, the single-stranded nucleic acid 1 and / or the single-stranded nucleic acid 2 each independently further comprising an extension chain, the extension chain being disposed at either end or in the middle of the single-stranded nucleic acid 1 and / or the single-stranded nucleic acid 2, the extension chain comprising a chain formed from one or more of the following molecules in random order: nucleosides, nucleotides or organic linkers, and the extension chain not being a sequence of multiple nucleotides when it is located on the single-stranded nucleic acid 2. Extending the length of the single-stranded nucleic acid at at least one end of the polypeptide is beneficial for reducing the phenomenon of stutter generated during a polypeptide nanopore sequencing process.

The present invention relates to polypeptides covalently bound to a molecular scaffold such that two or more peptide loops are present oppositely between the attachment points of the scaffold. In particular, the present invention describes peptides that are high-affinity binders of penicillin binding proteins (PBPs). The present invention also includes pharmaceutical compositions comprising the peptide ligands, and the use of the peptide ligands in inhibiting or treating diseases or disorders mediated by bacterial infection, or in providing prevention to subjects at risk of infection.

The invention relates to a method for screening tumor autoantibodies by using a small peptide display library. The method comprises the following steps: S1, obtaining a tumor mutation small peptide display library; s2, screening to obtain small peptides capable of interacting with serum; s3, analyzing protein and mutation information in the tumor mutation material to obtain an analysis result; and S4, calculating to obtain protein and mutation information with significant difference. Therefore, on the basis of obtaining a tumor mutation material (related), serum immunoprecipitation and high-throughput sequencing are combined, and a strategy for globally and unbiasedly researching the mutation-related tumor autoantibody is provided.

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.